Investor Day @ Antibiotice Iași
Antibiotice SA (symbol ATB) organized the Investor Day event on Monday, November 18, 2024, at its headquarters in Iași, providing an opportunity for dialogue with investors on topics of interest, as well as the company’s medium- and long-term development objectives and strategies. The event was attended by shareholders and investors of Antibiotice Iași, as well as representatives from companies such as Infinity Capital Investments, NN Group, Swiss Capital, and ESTINVEST.
The event focused on getting to know the industrial platform in Iași and presented the detailed objectives outlined in the business plan “The Future Together 2030”. This plan is supported by a mix of funding sources, including cohesion funds, state aid, PNRR, and InvestEU, through which the company accessed a loan from the European Investment Bank.
According to the business plan, by 2030, Antibiotice Iași aims to double its turnover to 250 million euros, multiply profits, expand its portfolio by more than 100 products, and internationalize its business, thereby increasing market shares both domestically and internationally.
Investors attending the event in person, as well as those watching the online broadcast, had the opportunity to ask questions to the Antibiotice management team about the investment plan until 2030, the process for setting prices for prescription medicines, the share of exports in total turnover, the RX and non-RX portfolio policy domestically, and the dividend distribution policy.
The Investor Day also included visits to key locations on the industrial platform in Iași, which are part of the company’s strategic investment plan for sustainable development. The visited areas included the Parenteral and Topical Products sections, the photovoltaic park that became operational this year, and the new finished products warehouse.
About Antibiotice
Antibiotice Iași has been for nearly seven decades the most important producer of generic medicines with Romanian capital, supporting the national healthcare system with over 180 products. It is also the largest exporter of the Romanian pharmaceutical industry. Antibiotice has consolidated sales in over 70 countries worldwide and is a global leader in the production of the active substance nystatin, also holding the reference standard awarded by the United States Pharmacopeia (USP).
Internationally, Antibiotice Iași is recognized as a major supplier of sterile injectable antibiotics for healthcare systems in the USA, UK, Canada, the Netherlands, Denmark, and Vietnam. Locally, Antibiotice Iași is the quantitative leader in the sterile injectable powders pharmaceutical form, topical products, as well as in the generic medicines and OTC drugs sold in Romanian hospitals.
The company’s alignment with international quality standards, rigorously imposed by the most regulated markets in the world, has resulted in obtaining European Good Manufacturing Practice (GMP) certifications for all 8 distinct production flows, as well as favorable approval from the US Food and Drug Administration (FDA) for both nystatin and sterile injectable powder manufacturing.
